Tyra Biosciences Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _________ to _________.Commission File Number: 001-40800 TYRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware(State or other jurisdiction ofincorporation or organization)2656 State StreetCarlsbad, California(Address of principal executive offices) Registrant’s telephone number, including area code: (619) 728-4760 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 8, 2026, the registrant had 59,470,381 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents FINANCIAL INFORMATIONCondensed Financial Statements2Condensed Balance Sheets2Condensed Statements of Operations and Comprehensive Loss3Condensed Statements of Stockholders’Equity4Condensed Statements of Cash Flows5Notes to the Condensed Financial Statements6Management’s Discussion and Analysis of Financial Condition and Results of Operations15Quantitative and Qualitative Disclosures About Market Risk23Controls and Procedures23OTHER INFORMATIONLegal Proceedings24Risk Factors24Unregistered Sales of Equity Securities and Use of Proceeds24Defaults Upon Senior Securities24Mine Safety Disclosures24Other Information24Exhibits2526 PART I.Item 1. Item 2.Item 3.Item 4.PART II.Item 1.Item 1A.Item 2.Item 3.Item 4.Item 5.Item 6.Signatures PART I—FINANCIAL INFORMATION Tyra Biosciences, Inc.Condensed Balance Sheets(in thousands, except share and per share data) Tyra Biosciences, Inc.Condensed Statements of Operations and Comprehensive Loss(unaudited)(in thousands, except share and per share data) Tyra Biosciences, Inc.Condensed Statements of Stockholders’ Equity(unaudited)(in thousands, except share amounts) Tyra Biosciences, Inc.Condensed Statements of Cash Flows(unaudited)(in thousands) Tyra Biosciences, Inc.Notes to the Condensed Financial Statements(unaudited) 1. Organization and Summary of Significant Accounting Policies Organization Tyra Biosciences, Inc. (the Company) was incorporated in the state of Delaware on August 2, 2018. The Company is aclinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities inFibroblast Growth Factor Receptor (FGFR) biology. The Company’s in-house precision medicine platform, SNÅP, enables rapidand precise drug design through iterative molecular SNÅPshots that help predict which product candidates may demonstrate thehighest potency, selectivity and tolerability. The Company’s focus is on applying its accelerated small molecule drug discoveryengine to develop therapies in targeted oncology and genetically defined conditions. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with generally acceptedaccounting principles in the United States (GAAP) for interim financial information and pursuant to the instructions of theSecurities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include allof the information and disclosures required by GAAP for complete financial statements. Any reference in these notes to applicableguidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates(ASU) promulgated by the Financia